These results revealed the cancer-regulating role of SMG-1 as a negative radiosensitivity mediator; (3) SMG-1 could serve as a prognostic indicator for the response of HNSCC patients to radiotherapy, which provides a new opportunity to guide precision medicine for HNSCC patients. This evidence concerns the gene SMG1 and cancer.